ETF Holdings Breakdown of EDIT

EDIT institutional holdings

The adjusted close for EDIT on 2025-11-11 was 2.66

The following institutional investment holdings of EDIT have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	61,643	USD 163,970 5.3%	2.66
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	61,643	USD 163,970 5.3%	2.66
Total =		123,286	USD 327,940

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with EDIT

Editas Medicine (NASDAQ:EDIT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock. A number of other research analysts also recently issued reports on EDIT. Wall Street Zen downgraded shares of Editas Medicine […] - 2025-09-08 03:10:44

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Hold” from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has received an average recommendation of “Hold” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, two have assigned a buy recommendation and two have assigned […] - 2025-08-06 05:14:49

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.36 Average Target Price from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, two have given a buy recommendation and two have […] - 2025-06-20 02:20:16

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method

Editas Medicine reports 58% mean editing in HSCs after single tLNP dose, aiding sickle cell and beta thalassemia treatments. - 2025-06-12 03:10:24

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. trimmed its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 3.8% during the first quarter, Holdings Channel reports. The firm owned 257,460 shares of the company’s stock after selling 10,298 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Editas Medicine were […] - 2025-06-10 04:58:49

Two Sigma Advisers LP Purchases 528,000 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

Two Sigma Advisers LP raised its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 46.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,657,000 shares of the company’s stock after purchasing an additional 528,000 shares during the period. […] - 2025-05-29 05:16:52

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.36 Consensus PT from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has earned an average rating of “Hold” from the fourteen research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, two have given a buy recommendation and two have issued a strong […] - 2025-05-26 02:48:57

Stifel Financial Corp Sells 287,718 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

Stifel Financial Corp lessened its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 46.0% during the 4th quarter, HoldingsChannel reports. The fund owned 337,158 shares of the company’s stock after selling 287,718 shares during the quarter. Stifel Financial Corp’s holdings in Editas Medicine were worth $428,000 at the end of the […] - 2025-05-13 04:50:58

Invesco Ltd. Has $127,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT)

Invesco Ltd. increased its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,164 shares of the company’s stock after acquiring an additional 8,448 shares during the quarter. Invesco Ltd.’s […] - 2025-05-06 04:28:46

Editas Medicine (NASDAQ:EDIT) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) to a strong-buy rating in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage currently has $3.00 price objective on the stock. Editas Medicine Stock Up 6.5 % Shares of EDIT stock opened at $1.65 on Monday. The firm has […] - 2025-05-01 04:40:50

Cantor Fitzgerald Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-Buy

Editas Medicine (NASDAQ:EDIT – Get Free Report) was upgraded by Cantor Fitzgerald from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports. Separately, HC Wainwright initiated coverage on Editas Medicine in a research report on Monday. They set a “buy” rating and a $3.00 price objective for the company. […] - 2025-05-01 02:38:48

XTX Topco Ltd Purchases 52,498 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

XTX Topco Ltd boosted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 99.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 105,056 shares of the company’s stock after acquiring an additional 52,498 shares during the quarter. XTX Topco Ltd’s holdings in Editas Medicine were worth $133,000 at the end […] - 2025-04-30 05:22:59

Raymond James Financial Inc. Takes Position in Editas Medicine, Inc. (NASDAQ:EDIT)

Raymond James Financial Inc. purchased a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 238,967 shares of the company’s stock, valued at approximately $303,000. A number of other institutional […] - 2025-04-10 04:14:58

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of “Hold” from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been given an average rating of “Hold” by the fourteen analysts that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and three have issued a buy recommendation on the company. […] - 2025-03-12 04:56:52

Ieq Capital LLC Makes New Investment in Editas Medicine, Inc. (NASDAQ:EDIT)

Ieq Capital LLC acquired a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 24,634 shares of the company’s stock, valued at approximately $31,000. A number of other institutional […] - 2025-03-03 06:50:57

Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $7.00

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and three have issued a buy recommendation on […] - 2025-02-18 04:44:58

Back to Listing

Disclaimer